Inverse association of p16 INK4a and p14 ARF methylation of the CDKN2a locus in different Gleason scores of prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 14, Issue 4, 2011, Pages 295-301

  Verdoodt, B ^a   Sommerer, F ^a   Palisaar, R J ^b   Noldus, J ^b   Vogt, M ^a   Nambiar, S ^a   Tannapfel, A ^a   Mirmohammadsadegh, A ^a   Neid, M ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

BMI1; p14 ARF; p16 INK4a; TMS1

Indexed keywords

BMI1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN TMS1; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; GENE LOCUS; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN METHYLATION;

AGED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; GENE EXPRESSION; GENETIC LOCI; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 80955158494     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.45     Document Type: Article

References (44)

1. Coleman MP, Gatta G, Verdecchia A, Estève J, Sant M, Storm H et al. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 2003; 14 (Suppl 5): v128-v149. (Pubitemid 46417466)
2. Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004; 17: 292-306. (Pubitemid 41646608)
3. Epstein JI. An update of the Gleason grading system. J Urol 2010; 183: 433-440.
4. Wright JL, Salinas CA, Lin DW, Kolb S, Koopmeiners J, Feng Z et al. Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4+3 and Gleason 3+4 tumors in a population based cohort. J Urol 2009; 182: 2702-2707.
5. Bradford TJ, Tomlins SA, Wang X, Chinnaiyan AM. Molecular markers of prostate cancer. Urol Oncol 2006; 24: 538-551. (Pubitemid 44810016)
6. Duhagon MA, Hurte EM, Sotelo-Silveira JR, Zhang X, Farrar WL. Genomic profiling of tumor initiating prostatospheres. BMC Genomics 2010; 11: 324.
7. Goo YA, Goodlett DR. Advances in proteomic prostate cancer biomarker discovery. J Proteomics 2010; 73: 1839-1850.
8. Kron KJ, Liu L, Pethe VV, Demetrashvili N, Nesbitt ME, Trachtenberg J et al. DNA methylation of HOXD3 as a marker of prostate cancer progression. Lab Invest 2010; 90: 1060-1067.
9. Sathyanarayana UG, Padar A, Suzuki M, Maruyama R, Shigematsu H, Hsieh JT et al. Aberrant promoter methylation of laminin-5-encoding genes in prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2003; 9: 6395-6400. (Pubitemid 38031825)
10. Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 2005; 97: 103-115. (Pubitemid 40277090)
11. Murphy TM, Perry AS, Lawler M. The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer. Endocr Relat Cancer 2008; 15: 11-25. (Pubitemid 351449724)
12. Hoque MO. DNA methylation changes in prostate cancer: current developments and future clinical implementation. Expert Rev Mol Diagn 2009; 9: 243-257.
13. Ramirez ML, Nelson EC, Evans CP. Beyond prostate-specific antigen: alternate serum markers. Prostate Cancer Prostatic Dis 2008; 11: 216-229.
14. Jeronimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G et al. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004; 10: 8472-8478. (Pubitemid 40053412)
15. Henrique R, Costa VL, Jeronimo C. Methylation-based biomar-kers for early detection of urological cancer. Crit Rev Oncog 2007; 13: 265-282. (Pubitemid 351655043)
16. Hoffmann MJ, Engers R, Florl AR, Otte AP, Muller M, Schulz WA. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methyla-tion changes in prostate cancer. Cancer Biol Ther 2007; 6: 1403-1412. (Pubitemid 351590350)
17. van Leenders GJ, Dukers D, Hessels D, van den Kieboom SW, Hulsbergen CA, Witjes JA et al. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 2007; 52: 455-463. (Pubitemid 46963432)
18. Fan C, He L, Kapoor A, Rybak AP, De Melo J, Cutz JC et al. PTEN inhibits BMI1 function independently of its phosphatase activity. Mol Cancer 2009; 8: 98.
19. Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV et al. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 2006; 5: 1886-1901. (Pubitemid 44435335)
20. Breuer RH, Snijders PJ, Sutedja GT, Sewalt RG, Otte AP, Postmus PE et al. Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions. Lung Cancer 2005; 48: 299-306. (Pubitemid 40693614)
21. Dhawan S, Tschen SI, Bhushan A. Bmi-1 regulates the Ink4a/Arf locus to control pancreatic beta-cell proliferation. Genes Dev 2009; 23: 906-911.
22. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev 2006; 20: 1123-1136.
23. Kim JH, Yoon SY, Kim CN, Joo JH, Moon SK, Choe IS et al. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 2004; 203: 217-224. (Pubitemid 38058689)
24. Sasaki M, Ikeda H, Sato Y, Nakanuma Y. Decreased expression of Bmi1 is closely associated with cellular senescence in small bile ducts in primary biliary cirrhosis. Am J Pathol 2006; 169: 831-845. (Pubitemid 44411951)
25. Gil J, Bernard D, Martinez D, Beach D. Polycomb CBX7 has a unifying role in cellular lifespan. Nat Cell Biol 2004; 6: 67-72. (Pubitemid 38425732)
26. Benbrahim-Tallaa L, Waterland RA, Dill AL, Webber MM, Waalkes MP. Tumor suppressor gene inactivation during cadmium-induced malignant transformation of human prostate cells correlates with overexpression of de novo DNA methyl-transferase. Environ Health Perspect 2007; 115: 1454-1459. (Pubitemid 47618087)
27. Bruggeman SW, Valk-Lingbeek ME, van der Stoop PP, Jacobs JJ, Kieboom K, Tanger E et al. Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev 2005; 19: 1438-1443. (Pubitemid 41003010)
28. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB et al. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 2000; 60: 129-133. (Pubitemid 30058742)
29. Conway KE, McConnell BB, Bowring CE, Donald CD, Warren ST, Vertino PM et al. TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers. Cancer Res 2000; 60: 6236-6242.
30. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-9826. (Pubitemid 26296693)
31. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001; 92: 276-284. (Pubitemid 32225381)
32. Kron K, Pethe V, Briollais L, Sadikovic B, Ozcelik H, Sunderji A et al. Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. PLoS One 2009; 4: e4830.
33. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C et al. Epigenetic stem cell signature in cancer. Nat Genet 2007; 39: 157-158. (Pubitemid 46184343)
34. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005; 435: 1262-1266. (Pubitemid 40943093)
35. Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, Mehra R et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007; 67: 10657-10663. (Pubitemid 350145890)
36. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-629.
37. Glinsky GV. 'Stemness' genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J Clin Oncol 2008; 26: 2846-2853.
38. Glinsky GV. Stem cell origin of death-from-cancer phenotypes of human prostate and breast cancers. Stem Cell Rev 2007; 3: 79-93. (Pubitemid 47472815)
39. ARF in human melanoma. J Natl Cancer Inst 2008; 100: 784-795. (Pubitemid 351809672)
40. ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma. J Invest Dermatol 2004; 122: 1284-1292. (Pubitemid 38651105)
41. Weber A, Bellmann U, Bootz F, Wittekind C, Tannapfel A. INK4a-ARF alterations and p53 mutations in primary and constitutive squamous cell carcinoma of the head and neck. Virchovs Arch 2002; 441: 133-142. (Pubitemid 34983979)
42. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hyper-methylation profile of human Cancer. Cancer Res 2001; 61: 3225-3229. (Pubitemid 32695003)
43. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell 2006; 127: 265-275. (Pubitemid 44572384)
44. Fan C, He L, Kapoor A, Gillis A, Rybak AP, Cutz JC et al. Bmi1 promotes prostate tumorigenesis via inhibiting p16(INK4A) and p14(ARF) expression. Biochim Biophys Acta 2008; 1782: 642-648.